Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis - 24/08/11
Leicester and Cambridge, United Kingdom
Abstract |
Background |
Nonasthmatic eosinophilic bronchitis is a condition characterized by the presence of eosinophilic airway inflammation in the absence of airflow obstruction or airway hyperresponsiveness. In asthma, the TH2-type cytokine IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. Whether the expression of IL-13 is different between these 2 conditions is unknown.
Objective |
We sought to investigate whether IL-13 expression is increased in asthma compared with eosinophilic bronchitis.
Methods |
Sputum samples from subjects with mild asthma (n=30) and eosinophilic bronchitis (n=15) and normal controls (n=16) were dialyzed, and IL-13 concentration was measured by ELISA. In a subgroup of these patients, IL-13 protein expression in bronchial biopsies was assessed by immunohistochemistry.
Results |
The concentration of sputum IL-13 was higher in patients with mild asthma than in normal controls (P=.03) and in patients with eosinophilic bronchitis (P=.03). The median (interquartile range) number of IL-13+ cells/mm2 submucosa was significantly higher in asthma 4 (8) than eosinophilic bronchitis 1.7 (1.9) and normal controls 0.5 (1.1; P=.004). Eighty-three percent of the cells expressing IL-13 in the submucosa were eosinophils, and 8% were mast cells. The median (interquartile range) proportion of eosinophils that expressed IL-13 was higher in the subjects with asthma, 16 (10)%, than those with eosinophilic bronchitis, 7 (3)% (P=.02).
Conclusion |
The increased expression of IL-13 in asthma compared with eosinophilic bronchitis supports the concept that IL-13 may play a critical role in the pathophysiology of asthma.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, IL-13, eosinophilic bronchitis, eosinophils, mast cells
Abbreviations used : MBP, UK
Plan
Supported by a grant from Asthma UK and Cambridge Antibody Technology. Dr Brightling is supported by a DoH Clinician Scientist Award. |
Vol 114 - N° 5
P. 1106-1109 - novembre 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?